Fortecortin Inject 4 mg Injektionslösung Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

fortecortin inject 4 mg injektionslösung

Fortecortin Inject 4 mg Solution injectable Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

fortecortin inject 4 mg solution injectable

Fortecortin Inject 8 mg Injektionslösung Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

fortecortin inject 8 mg injektionslösung

Fortecortin Inject 8 mg Solution injectable Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

fortecortin inject 8 mg solution injectable

VASPIT CREMA 30G 0,75% Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

vaspit crema 30g 0,75%

intendis spa - fluocortin estere butilico - crema - "0,75 % crema" 1 tubo da 30 g

Lucentis Unione Europea - italiano - EMA (European Medicines Agency)

lucentis

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologici - lucentis è indicato negli adulti per:il trattamento di neovascolare (bagnato) degenerazione maculare legata all'età (amd), il trattamento delle disabilità visiva a causa di coroideale neovascularisation (cnv)il trattamento della disabilità visiva a causa di edema maculare diabetico (dme)il trattamento della disabilità visiva a causa di edema maculare secondario a occlusione della vena retinica (ramo rvo centrale o rvo).

Byooviz Unione Europea - italiano - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologici - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci Unione Europea - italiano - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Unione Europea - italiano - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Macugen Unione Europea - italiano - EMA (European Medicines Agency)

macugen

pharmaswiss ceska republika s.r.o - pegaptanib - degenerazione maculare umida - oftalmologici - macugen è indicato per il trattamento di (bagnato) relativo all'età degenerazione maculare neovascolare (amd).